Business Insider Discussed Findings of Foley’s Connected Cars & Autonomous Vehicles Survey
27 October 2017
Business Insider reported on the findings of Foley’s 2017 Connected Cars & Autonomous Vehicles Survey, which shed light on the biggest legal concerns about connected and self-driving cars among automotive and technology professionals.
The survey, which had 83 auto and tech executive-level respondents, found that the industries’ highest concern about connected and self-driving cars is cyberattacks and the second-highest concern is intellectual property protection.
Read the full Business Insider story on the survey results here: “Self-Driving Cars Hitting the Road Have Auto and Tech Execs Worried about Cyber Attacks.”
The survey, which had 83 auto and tech executive-level respondents, found that the industries’ highest concern about connected and self-driving cars is cyberattacks and the second-highest concern is intellectual property protection.
Read the full Business Insider story on the survey results here: “Self-Driving Cars Hitting the Road Have Auto and Tech Execs Worried about Cyber Attacks.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”